Text Size

A A A

Search


 

Home | Clinical Trials

FDA Approved Drugs » 2012
Medical Areas: Neurology | Pediatrics/Neonatology | Family Medicine | Genetic Disease

View By:Year | Company | Conditions | Therapeutic Areas | Drug Names

Oxtellar XR (oxcarbazepine extended release)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company: Supernus Pharmaceuticals
Approval Status: Approved October 2012
Treatment Area: partial seizures in adults and in children 6 years to 17 years of age

General Information

Oxtellar XR is an extended release, once daily formulation of oxcarbazepine, a currently approved anti-epileptic drug. Oxcarbazepine produces blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of synaptic impulses. These actions are thought to be important in the prevention of seizure spread in the intact brain.

Oxtellar XR is specifically indicated as adjunctive therapy of partial seizures in adults and in children 6 years to 17 years of age.

Oxtellar XR is supplied as a tablet for oral administration. Oxtellar XR should be administered as a single daily dose taken on an empty stomach (at least 1 hour before or at least 2 hours after meals). The tablets should be swallowed whole. The recommended daily dose of Oxtellar XR is as follows:
Adults
1,200 mg to 2,400 mg per day, given once daily. Initiate treatment at a dose of 600 mg per day given once daily for one week. Subsequent dose increases can be made at weekly intervals in 600 mg per day increments to achieve the recommended daily dose.
Pediatrics 6 to 17 years of Age
Initiate treatment at a daily dose of 8 mg/kg to 10 mg/kg once daily, not to exceed 600 mg per day in the first week. Subsequent dose increases can be made at weekly intervals in 8 mg/kg to 10 mg/kg increments once daily, not to exceed 600 mg, to achieve the target maintenance daily dose, based on weight.

Clinical Results

FDA Approval
The FDA approval of Oxtellar XR for the treatment of partial seizures in pediatrics was based on adequate and well-controlled studies of Oxtellar XR in adults, along with clinical trials of immediate-release oxcarbazepine in children, and on pharmacokinetic evaluations of the use of Oxtellar XR in children.
Oxtellar XR Primary Trial
The multicenter, randomized, double-blind, placebo-controlled, three-arm, parallel-group study enrolled 366 adults with refractory partial epilepsy. All subjects had at least three partial seizures per 28 days during an 8 week Baseline Period, were receiving treatment with at least one to three antiepileptic drugs and were on stable treatment for a minimum of 4 weeks. The subjects received Oxtellar XR (1200 or 2400 mg/day) or placebo. The treatment period included a 4 week Titration Phase followed by a 12 week Maintenance Phase. The primary endpoint of the study was median percentage change from baseline in seizure frequency per 28 days during the treatment period relative to the baseline period. The results are as follows: Oxtellar XR 1200mg/day: -38.2 % (p=0.078), Oxtellar XR 2400mg/day: -42.9 % (p=0.003) and placebo: -28.7 %.
Immediate-Release Oxcarbazepine Adjunctive Therapy Trials
The effectiveness of immediate-release oxcarbazepine as an adjunctive therapy for partial seizures in adults was demonstrated at doses of 600mg per day, 1200mg per day and 2400mg per day (divided twice daily) in a randomized, double-blind, placebo-controlled trial. All doses resulted in a statistically significant reduction in seizure frequency when compared to placebo (p<0.05). The effectiveness of immediate-release oxcarbazepine in doses of 30-46 mg/kg/day, depending on baseline weight, as an adjunctive therapy for partial seizures in children 3 years to 17 years of age was studied in a randomized, double-blind, placebo-controlled trial. Oxcarbazepine in the single weight based dose group resulted in a statistically significant reduction in seizure frequency when compared to placebo (p<0.05).

Side Effects

Adverse events associated with the use of Oxtellar XR may include, but are not limited to, the following:

  • dizziness
  • somnolence
  • headache
  • balance disorder
  • tremor
  • vomiting
  • diplopia
  • asthenia
  • fatigue

Mechanism of Action

Oxtellar XR is an extended release, once daily formulation of oxcarbazepine, a currently approved anti-epileptic drug. Oxcarbazepine produces blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of synaptic impulses. These actions are thought to be important in the prevention of seizure spread in the intact brain. In addition, increased potassium conductance and modulation of high-voltage activated calcium channels may contribute to the anticonvulsant effects of the drug.

Additional Information

For additional information regarding Oxtellar XR or partial seizures, please visit the Supernus web page.


 Back to Top | Printer Friendly Version

Get Involved

Stroke and You

Our Mission Statement

National Stroke Association’s mission is to reduce the incidence and impact of stroke by developing compelling education and programs focused on prevention, treatment, rehabilitation and support for all impacted by stroke.

National Stroke Association

1-800-STROKES
1-800-787-6537
9707 E. Easter Lane, Suite B
Centennial, CO 80112
info@stroke.org